DC-HIL/Glycoprotein Nmb Promotes Growth of Melanoma in Mice by Inhibiting the Activation of Tumor-Reactive T Cells
Open Access
- 14 July 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (14), 5778-5787
- https://doi.org/10.1158/0008-5472.can-09-2538
Abstract
DC-HIL/glycoprotein nmb (Gpnmb) expressed on antigen-presenting cells attenuates T-cell activation by binding to syndecan-4 (SD-4) on activated T cells. Because DC-HIL/Gpnmb is expressed abundantly by mouse and human melanoma lines, we posited that melanoma-associated DC-HIL/Gpnmb exerts similar inhibitory function on melanoma-reactive T cells. We generated small interfering RNA–transfected B16F10 melanoma cells to completely knock down DC-HIL/Gpnmb expression, with no alteration in cell morphology, melanin synthesis, or MHC class I expression. This knockdown had no effect on B16F10 proliferation in vitro or entry into the cell cycle following growth stimulation, but it markedly reduced the growth of these cells in vivo following their s.c. injection into syngeneic immunocompetent (but not immunodeficient) mice. This reduction in tumor growth was due most likely to an augmented capacity of DC-HIL–knocked down B16F10 cells (compared with controls) to activate melanoma-reactive T cells as documented in vitro and in mice. Whereas DC-HIL knockdown had no effect on susceptibility of melanoma to killing by cytotoxic T cells, blocking SD-4 function enhanced the reactivity of CD8+ T cells to melanoma-associated antigens on parental B16F10 cells. Using an assay examining the spread to the lung following i.v. injection, DC-HIL–knocked down cells produced lung foci at similar numbers compared with that produced by control cells, but the size of the former foci was significantly smaller than the latter. We conclude that DC-HIL/Gpnmb confers upon melanoma the ability to downregulate the activation of melanoma-reactive T cells, thereby allowing melanoma to evade immunologic recognition and destruction. As such, the DC-HIL/SD-4 pathway is a potentially useful target for antimelanoma immunotherapy. Cancer Res; 70(14); 5778–87. ©2010 AACR.Other Versions
This publication has 41 references indexed in Scilit:
- Role of human HGFIN/nmbin breast cancerBreast Cancer Research, 2007
- Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing MicrovesiclesThe Journal of Experimental Medicine, 2002
- The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune ResponsesAnnual Review of Immunology, 2002
- Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblastsJournal of Cellular Biochemistry, 2001
- Molecular Cloning of a Dendritic Cell-associated Transmembrane Protein, DC-HIL, That Promotes RGD-dependent Adhesion of Endothelial Cells through Recognition of Heparan Sulfate ProteoglycansOnline Journal of Public Health Informatics, 2001
- PD-L2 is a second ligand for PD-1 and inhibits T cell activationNature Immunology, 2001
- Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.2001
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000
- Small GTPase Rab3A is Associated with Melanosomes in Melanoma CellsPigment Cell Research, 2000
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretionNature Medicine, 1999